{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T01:50:13Z","timestamp":1793065813895,"version":"4.5.0"},"reference-count":52,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2024,11,1]]},"abstract":"\n Importance<\/jats:title>\n Multiple studies suggest that comorbidity worsens clinically relevant outcomes in multiple sclerosis (MS), including the severity of disability at diagnosis and rate of disability worsening after diagnosis. However, less is known regarding the association of comorbidity with measures of disease activity, such as relapse rate and magnetic resonance imaging lesion accrual, which are relevant to clinicians and clinical trialists.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate the association of comorbidities with disease activity in clinical trials of disease-modifying therapies (DMTs) in populations with MS.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n A 2-stage meta-analytic approach was used in this cohort study of individual participant data from phase 3 clinical trials of MS DMTs that had 2 years of follow-up and were conducted from November 2001 to March 2018. Data were analyzed from February 2023 to June 2024.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n Comorbidity burden and individual comorbidities present at trial enrollment, including hypertension; hyperlipidemia; functional cardiovascular disease, ischemic heart, cerebrovascular, and peripheral vascular disease; diabetes; autoimmune thyroid and miscellaneous autoimmune conditions; migraine; lung and skin conditions; depression; anxiety; and other psychiatric disorders.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The main outcome was evidence of disease activity (EDA) over 2 years of follow-up, defined as confirmed relapse activity, disability worsening, or any new lesions on magnetic resonance imaging.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 16\u202f794 participants with MS were included from 17 clinical trials (67.2% female). Over the 2-year follow-up, 61.0% (95% CI, 56.2%-66.3%;\n I<\/jats:italic>\n 2<\/jats:sup>\n \u2009=\u200997.9%) of the pooled trials had EDA. After adjusting for multiple factors, the presence of 3 or more comorbidities was associated with an increased hazard of EDA (adjusted hazard ratio [AHR], 1.14; 95% CI, 1.02-1.28) compared with no comorbidity. Presence of 2 or more cardiometabolic conditions was also associated with an increased hazard of EDA (AHR, 1.21; 95% CI, 1.08-1.37) compared with no cardiometabolic comorbidity. Presence of 1 psychiatric disorder was associated with an increased hazard of EDA (AHR, 1.07; 95% CI, 1.02-1.14).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this study, a higher burden of comorbidity was associated with worse clinical outcomes in people with MS, although comorbidity could potentially be a partial mediator of other negative prognostic factors. Our findings suggest a substantial adverse association of the comorbidities investigated with MS disease activity and that prevention and management of comorbidities should be a pressing concern in clinical practice.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamaneurol.2024.2920","type":"journal-article","created":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T06:30:28Z","timestamp":1726641028000},"page":"1170","source":"Crossref","is-referenced-by-count":55,"title":["Comorbidity and Disease Activity in Multiple Sclerosis"],"prefix":"10.1001","volume":"81","author":[{"given":"Amber","family":"Salter","sequence":"first","affiliation":[{"name":"Department of Neurology, Section on Statistical Planning and Analysis, UT Southwestern Medical Center, Dallas, Texas"},{"name":"Peter O\u2019Donnell Jr. Brain Institute, University of Texas Southwestern Medical Center, Dallas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Lancia","sequence":"additional","affiliation":[{"name":"Department of Neurology, Section on Statistical Planning and Analysis, UT Southwestern Medical Center, Dallas, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaarina","family":"Kowalec","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada"},{"name":"Department of Medical Epidemiology & Biostatistics, Karolinska Institutet, Solna, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn C.","family":"Fitzgerald","sequence":"additional","affiliation":[{"name":"Department of Neurology, Johns Hopkins School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth Ann","family":"Marrie","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada"},{"name":"Department of Community Health Sciences, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"6","key":"noi240056r1","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/nrneurol.2017.33","article-title":"Comorbidity in multiple sclerosis: implications for patient care.","volume":"13","author":"Marrie","year":"2017","journal-title":"Nat Rev Neurol"},{"issue":"22","key":"noi240056r2","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1212\/WNL.0000000000004686","article-title":"Assessing association of comorbidities with treatment choice and persistence in MS: a real-life multicenter study.","volume":"89","author":"Laroni","year":"2017","journal-title":"Neurology"},{"issue":"14","key":"noi240056r3","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1212\/WNL.0000000000002543","article-title":"Examining the effects of comorbidities on disease-modifying therapy use in multiple sclerosis.","volume":"86","author":"Zhang","year":"2016","journal-title":"Neurology"},{"issue":"24","key":"noi240056r4","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1212\/WNL.0000000000004716","article-title":"Comorbidity increases the risk of relapse in multiple sclerosis: a prospective study.","volume":"89","author":"Kowalec","year":"2017","journal-title":"Neurology"},{"issue":"2","key":"noi240056r5","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1159\/000442203","article-title":"Frequency of comorbidities and their association with clinical disability and relapse in multiple sclerosis.","volume":"46","author":"Tettey","year":"2016","journal-title":"Neuroepidemiology"},{"issue":"11","key":"noi240056r6","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1136\/jnnp-2012-304740","article-title":"Lipid profiles are associated with lesion formation over 24 months in interferon-\u00df treated patients following the first demyelinating event.","volume":"84","author":"Weinstock-Guttman","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"noi240056r7","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/1742-2094-8-127","article-title":"Serum lipid profiles are associated with disability and MRI outcomes in multiple sclerosis.","volume":"8","author":"Weinstock-Guttman","year":"2011","journal-title":"J Neuroinflammation"},{"issue":"8","key":"noi240056r8","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1136\/jnnp-2013-307106","article-title":"Apolipoproteins are associated with new MRI lesions and deep grey matter atrophy in clinically isolated syndromes.","volume":"85","author":"Browne","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"noi240056r9","doi-asserted-by":"publisher","first-page":"e446","DOI":"10.1212\/WNL.0000000000010024","article-title":"Comorbidity is associated with disease activity in MS: findings from the CombiRx trial.","volume":"95","author":"Salter","year":"2020","journal-title":"Neurology"},{"issue":"5","key":"noi240056r10","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209135","article-title":"Investigating the prevalence of comorbidity in multiple sclerosis clinical trial populations.","volume":"102","author":"Salter","year":"2024","journal-title":"Neurology"},{"issue":"13","key":"noi240056r11","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1212\/WNL.0b013e3181d6b125","article-title":"Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis.","volume":"74","author":"Marrie","year":"2010","journal-title":"Neurology"},{"issue":"13","key":"noi240056r12","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1177\/1352458514533162","article-title":"An adverse lipid profile is associated with disability and progression in disability, in people with MS.","volume":"20","author":"Tettey","year":"2014","journal-title":"Mult Scler"},{"issue":"15","key":"noi240056r13","doi-asserted-by":"publisher","first-page":"e1316","DOI":"10.1212\/WNL.0000000000005302","article-title":"Psychiatric comorbidity is associated with disability progression in multiple sclerosis.","volume":"90","author":"McKay","year":"2018","journal-title":"Neurology"},{"issue":"1","key":"noi240056r14","first-page":"103","article-title":"Maelstrom research guidelines for rigorous retrospective data harmonization.","volume":"46","author":"Fortier","year":"2017","journal-title":"Int J Epidemiol"},{"issue":"6","key":"noi240056r15","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1056\/NEJMoa1917246","article-title":"Ofatumumab versus teriflunomide in multiple sclerosis.","volume":"383","author":"Hauser","year":"2020","journal-title":"N Engl J Med"},{"issue":"15","key":"noi240056r16","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1212\/WNL.0000000000002471","article-title":"The challenge of comorbidity in clinical trials for multiple sclerosis.","volume":"86","author":"Marrie","year":"2016","journal-title":"Neurology"},{"issue":"9","key":"noi240056r17","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1177\/1352458517703193","article-title":"\u201cNo evident disease activity\u201d: the use of combined assessments in the management of patients with multiple sclerosis.","volume":"23","author":"Giovannoni","year":"2017","journal-title":"Mult Scler"},{"issue":"5","key":"noi240056r18","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1056\/NEJMoa0907839","article-title":"Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.","volume":"362","author":"Cohen","year":"2010","journal-title":"N Engl J Med"},{"issue":"5","key":"noi240056r19","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1056\/NEJMoa0909494","article-title":"A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.","volume":"362","author":"Kappos","year":"2010","journal-title":"N Engl J Med"},{"issue":"6","key":"noi240056r20","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S1474-4422(14)70049-3","article-title":"Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.","volume":"13","author":"Calabresi","year":"2014","journal-title":"Lancet Neurol"},{"issue":"9856","key":"noi240056r21","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","article-title":"Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.","volume":"380","author":"Cohen","year":"2012","journal-title":"Lancet"},{"issue":"3","key":"noi240056r22","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials.","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"issue":"3","key":"noi240056r23","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/jrsm.1547","article-title":"Meta-analysis of prevalence: I2 statistic and how to deal with heterogeneity.","volume":"13","author":"Migliavaca","year":"2022","journal-title":"Res Synth Methods"},{"issue":"7","key":"noi240056r24","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/S1474-4422(14)70068-7","article-title":"Pegylated interferon \u00df-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.","volume":"13","author":"Calabresi","year":"2014","journal-title":"Lancet Neurol"},{"issue":"12","key":"noi240056r25","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1056\/NEJMoa1206328","article-title":"Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.","volume":"367","author":"Fox","year":"2012","journal-title":"N Engl J Med"},{"issue":"3","key":"noi240056r26","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/ana.23863","article-title":"Randomized study combining interferon and glatiramer acetate in multiple sclerosis.","volume":"73","author":"Lublin","year":"2013","journal-title":"Ann Neurol"},{"issue":"3","key":"noi240056r27","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis.","volume":"376","author":"Montalban","year":"2017","journal-title":"N Engl J Med"},{"issue":"9","key":"noi240056r28","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.","volume":"354","author":"Polman","year":"2006","journal-title":"N Engl J Med"},{"issue":"9","key":"noi240056r29","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1056\/NEJMoa044396","article-title":"Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.","volume":"354","author":"Rudick","year":"2006","journal-title":"N Engl J Med"},{"issue":"5","key":"noi240056r30","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1056\/NEJMoa0902533","article-title":"A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.","volume":"362","author":"Giovannoni","year":"2010","journal-title":"N Engl J Med"},{"issue":"9856","key":"noi240056r31","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","article-title":"Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.","volume":"380","author":"Coles","year":"2012","journal-title":"Lancet"},{"issue":"12","key":"noi240056r32","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","article-title":"Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.","volume":"367","author":"Gold","year":"2012","journal-title":"N Engl J Med"},{"issue":"10023","key":"noi240056r33","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/S0140-6736(15)01314-8","article-title":"Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial.","volume":"387","author":"Lublin","year":"2016","journal-title":"Lancet"},{"issue":"3","key":"noi240056r34","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis.","volume":"376","author":"Hauser","journal-title":"N Engl J Med"},{"issue":"5","key":"noi240056r35","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/S1474-4422(18)30069-3","article-title":"Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.","volume":"17","author":"Kapoor","year":"2018","journal-title":"Lancet Neurol"},{"issue":"5","key":"noi240056r36","doi-asserted-by":"publisher","first-page":"e419","DOI":"10.1212\/WNL.0000000000004885","article-title":"Effects of physical comorbidities on disability progression in multiple sclerosis.","volume":"90","author":"Zhang","year":"2018","journal-title":"Neurology"},{"issue":"2","key":"noi240056r37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0148573","article-title":"Prevalence of comorbidities, overweight and obesity in an international sample of people with multiple sclerosis and associations with modifiable lifestyle factors.","volume":"11","author":"Marck","year":"2016","journal-title":"PLoS One"},{"issue":"3","key":"noi240056r38","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1111\/ene.14608","article-title":"The Framingham cardiovascular risk score and 5-year progression of multiple sclerosis.","volume":"28","author":"Petruzzo","year":"2021","journal-title":"Eur J Neurol"},{"key":"noi240056r39","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103249","article-title":"Comorbidity and persistence of disease-modifying therapy use in relapsing remitting multiple sclerosis.","volume":"56","author":"Parks","year":"2021","journal-title":"Mult Scler Relat Disord"},{"issue":"4","key":"noi240056r40","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1177\/13524585211031128","article-title":"Risk of depression in multiple sclerosis across disease-modifying therapies.","volume":"28","author":"Longinetti","year":"2022","journal-title":"Mult Scler"},{"issue":"8","key":"noi240056r41","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1111\/ene.12720","article-title":"The Framingham cardiovascular risk score in multiple sclerosis.","volume":"22","author":"Moccia","year":"2015","journal-title":"Eur J Neurol"},{"issue":"7","key":"noi240056r42","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1001\/jamaneurol.2020.0664","article-title":"Evaluating the risk of macrovascular events and mortality among people with multiple sclerosis in England.","volume":"77","author":"Palladino","year":"2020","journal-title":"JAMA Neurol"},{"issue":"12","key":"noi240056r43","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1177\/1352458520984746","article-title":"Vascular comorbidity is associated with lower brain volumes and lower neuroperformance in a large multiple sclerosis cohort.","volume":"27","author":"Fitzgerald","year":"2021","journal-title":"Mult Scler"},{"issue":"2","key":"noi240056r44","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1212\/CPJ.0000000000000230","article-title":"Differing trends in the incidence of vascular comorbidity in MS and the general population.","volume":"6","author":"Marrie","year":"2016","journal-title":"Neurol Clin Pract"},{"key":"noi240056r45","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.101423","article-title":"Incident cardiovascular disease in patients diagnosed with multiple sclerosis: a multi-database study.","volume":"37","author":"Persson","year":"2020","journal-title":"Mult Scler Relat Disord"},{"issue":"24","key":"noi240056r46","doi-asserted-by":"publisher","first-page":"e2216","DOI":"10.1212\/WNL.0000000000008617","article-title":"Disability worsening among persons with multiple sclerosis and depression: a Swedish cohort study.","volume":"93","author":"Binzer","year":"2019","journal-title":"Neurology"},{"issue":"5","key":"noi240056r47","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-007806","article-title":"Multiple sclerosis course and clinical outcomes in patients with comorbid asthma: a survey study.","volume":"5","author":"Manouchehrinia","year":"2015","journal-title":"BMJ Open"},{"issue":"9","key":"noi240056r48","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/S2213-2600(17)30293-X","article-title":"Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015.","volume":"5","author":"GBD 2015 Chronic Respiratory Disease Collaborators","year":"2017","journal-title":"Lancet Respir Med"},{"key":"noi240056r49","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.msard.2016.05.009","article-title":"Chronic lung disease and multiple sclerosis: incidence, prevalence, and temporal trends.","volume":"8","author":"Marrie","year":"2016","journal-title":"Mult Scler Relat Disord"},{"key":"noi240056r50","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.nicl.2015.07.013","article-title":"Increased contrast enhancing lesion activity in relapsing-remitting multiple sclerosis migraine patients.","volume":"9","author":"Graziano","year":"2015","journal-title":"Neuroimage Clin"},{"key":"noi240056r51","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1197195","article-title":"Etiology, effects and management of comorbidities in multiple sclerosis: recent advances.","volume":"14","author":"Marrie","year":"2023","journal-title":"Front Immunol"},{"issue":"9","key":"noi240056r52","doi-asserted-by":"publisher","first-page":"e880","DOI":"10.1212\/WNL.0000000000013230","article-title":"Enrollment of non-white participants and reporting of race and ethnicity in phase III trials of multiple sclerosis DMTs: a systematic review.","volume":"98","author":"Onuorah","year":"2022","journal-title":"Neurology"}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/articlepdf\/2823966\/jamaneurology_salter_2024_oi_240056_1731111359.24483.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T11:01:06Z","timestamp":1731322866000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2823966"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,1]]},"references-count":52,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2024.2920","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,1]]}}}